Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Other Accumulated Expenses (2021 - 2022)

Amylyx Pharmaceuticals has reported Other Accumulated Expenses over the past 2 years, most recently at $1.0 million for Q4 2022.

  • Quarterly results put Other Accumulated Expenses at $1.0 million for Q4 2022, up 289.53% from a year ago — trailing twelve months through Dec 2022 was $1.0 million (up 289.53% YoY), and the annual figure for FY2022 was $1.0 million, up 289.53%.
  • Other Accumulated Expenses for Q4 2022 was $1.0 million at Amylyx Pharmaceuticals, up from $356000.0 in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for AMLX hit a ceiling of $1.0 million in Q4 2022 and a floor of $258000.0 in Q4 2021.